ICARISIDE II
Icariside II is a glycosyloxyflavone that is 3,5,7-trihydroxy-4'-methoxy-8-prenylflavone in which the hydroxy group at position 3 has been converted into its alpha-L-rhamnopyranoside.
定義
Icariside II is a glycosyloxyflavone that is 3,5,7-trihydroxy-4'-methoxy-8-prenylflavone in which the hydroxy group at position 3 has been converted into its alpha-L-rhamnopyranoside. It has a role as an antineoplastic agent, an anti-inflammatory agent, an apoptosis inducer and a plant metabolite. It is functionally related to an alpha-L-rhamnopyranose.
出典: PubChem
化粧品での役割
安全性・規制情報
Other restriction: ban substances that deplete the ozone layer
出典: EU CosIng 成分リスト
詳しい資料 — 表示名・識別番号・物性・試験記録・文献
公式表示名・定義
日本化粧品工業会の表示名称 イカリシドⅡ: 本品は、次の化学式で表される有機化合物である。
出典: 日本化粧品工業会 表示名称
別名・識別情報
- CAS No.化学物質登録番号
- 113558-15-9
- DTXSID米国EPA化学物質番号
- DTXSID40150457
- DTXCID米国EPA化合物番号
- DTXCID4072948
- IUPAC
- 5,7-Dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)-4-oxo-4H-1-benzopyran-3-yl 6-deoxy-alpha-L-mannopyranoside
- 分子式
- C27H30O10
- 分子量
- 514.527 g/mol
製品が実際に使っている用途
米国EPAにこの成分を届け出た製品5件の用途です。化粧品以外の製品も含まれるため、上の数行がこの成分の主な使い道といえます。
- Softener and conditioner2
- Bleaching agent1
- Humectant1
- Antioxidant1
出典: 米国EPA CompTox
関連文献
- Xianling Lianxia formula enhances the inhibitory effects of trastuzumab on HER2-positive breast cancer · 2023
- Epimedium brevicornum Maxim. Extract exhibits pigmentation by melanin biosynthesis and melanosome biogenesis/transfer · 2022
- Icariside II overcomes BRAF inhibitor resistance in melanoma by inducing ROS production and inhibiting MITF. · 2020
- Blockade of epidermal growth factor receptor/mammalian target of rapamycin pathway by Icariside II results in reduced cell proliferation of osteosarcoma cells. · 2014
- Icariside II induces apoptosis via inhibition of the EGFR pathways in A431 human epidermoid carcinoma cells. · 2013